Literature DB >> 20034483

Apolipoprotein E protects cultured pericytes and astrocytes from D-Abeta(1-40)-mediated cell death.

Ilona B Bruinsma1, Micha M M Wilhelmus, Matthijs Kox, Robert Veerhuis, Robert M W de Waal, Marcel M Verbeek.   

Abstract

Cerebral amyloid angiopathy (CAA) is a common pathological finding in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis of the Dutch type; in this latter condition it is caused by deposition of mutated amyloid beta protein (Abeta Glu22Gln; D-Abeta(1-40)). Previously, we found a dependence of the Abeta-mediated toxicity and apolipoprotein E (apoE) production by cultured pericytes on apoE genotype. Given their close association with the cerebrovascular wall both astrocytes and pericytes may be involved in CAA development, a process that includes Abeta deposition and clearance and that may be affected by interaction with locally produced apolipoprotein E (apoE). Although astrocytes are regarded as the major source of apolipoprotein E (apoE) in the brain, also pericytes produce apoE. In this study we compared the apoE production capacity, the effects of apoE on D-Abeta(1-40) internalization, D-Abeta(1-40) cell surface accumulation and the vulnerability for D-Abeta(1-40)-induced toxicity of either cell type in order to quantify the relative contributions of astrocytes and pericytes in the various processes that contribute to CAA formation. Strikingly, cultured astrocytes produced only 3-10% of the apoE amounts produced by pericytes. Furthermore, pericytes with the apoE epsilon4 allele produced three times less apoE and were more vulnerable to D-Abeta(1-40) treatment than pericytes without an epsilon4 allele. Such relations were not observed with astrocytes in vitro. Both pericytes and astrocytes, however, were protected from Abeta-induced cytotoxicity by high levels of pericyte-derived apoE, but not recombinant apoE. In addition, pericyte-derived apoE dose-dependently decreased both internalization of Abeta and Abeta accumulation at the cell surface in either cell type. The present data suggest that apoE produced by pericytes, rather than astrocyte-produced apoE, modulates Abeta cytotoxicity and Abeta removal near the vasculature in the brain. Furthermore, since apoE production in pericytes is genotype dependent, this may contribute to the apoE genotype-dependent development of CAA in vivo. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20034483     DOI: 10.1016/j.brainres.2009.12.039

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

Review 1.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 2.  The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD.

Authors:  Sally Hunter; Thomas Arendt; Carol Brayne
Journal:  Mol Neurobiol       Date:  2013-04-03       Impact factor: 5.590

Review 3.  APOE in the normal brain.

Authors:  Sarah A Flowers; G William Rebeck
Journal:  Neurobiol Dis       Date:  2020-01-03       Impact factor: 5.996

Review 4.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

Review 5.  The Role of ApoE Expression and Variability of Its Glycosylation in Human Reproductive Health in the Light of Current Information.

Authors:  Monika Kacperczyk; Agnieszka Kmieciak; Ewa Maria Kratz
Journal:  Int J Mol Sci       Date:  2021-07-04       Impact factor: 5.923

6.  Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan.

Authors:  Yuan Fu; Jing Zhao; Yuka Atagi; Henrietta M Nielsen; Chia-Chen Liu; Honghua Zheng; Mitsuru Shinohara; Takahisa Kanekiyo; Guojun Bu
Journal:  Mol Neurodegener       Date:  2016-05-05       Impact factor: 14.195

Review 7.  Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy?

Authors:  T Michael De Silva; Alyson A Miller
Journal:  Front Pharmacol       Date:  2016-03-17       Impact factor: 5.810

8.  Analysis of the brain mural cell transcriptome.

Authors:  Liqun He; Michael Vanlandewijck; Elisabeth Raschperger; Maarja Andaloussi Mäe; Bongnam Jung; Thibaud Lebouvier; Koji Ando; Jennifer Hofmann; Annika Keller; Christer Betsholtz
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

9.  Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier.

Authors:  Elisanne A L M Biemans; Lieke Jäkel; Robert M W de Waal; H Bea Kuiperij; Marcel M Verbeek
Journal:  J Neurosci Res       Date:  2016-10-11       Impact factor: 4.164

10.  Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.

Authors:  Qingyi Ma; Zhen Zhao; Abhay P Sagare; Yingxi Wu; Min Wang; Nelly Chuqui Owens; Philip B Verghese; Joachim Herz; David M Holtzman; Berislav V Zlokovic
Journal:  Mol Neurodegener       Date:  2018-10-19       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.